Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE SULFA versus SULSTER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE SULFA versus SULSTER.
ILOSONE SULFA vs SULSTER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ilosone (erythromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Sulfa (sulfisoxazole) is a sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. The combination provides synergistic bacteriostatic activity.
Sulster is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thus bacterial DNA replication.
Each 5 mL suspension contains 250 mg erythromycin base and 600 mg sulfisoxazole; typical adult dose is 10 mL (2 tsp) every 6 hours, not to exceed 40 mL/day.
2.5 mg orally twice daily.
None Documented
None Documented
Erythromycin: 1.5-2 hours; Sulfisoxazole: 4-7 hours; clinical context: dose adjustment in renal impairment (CrCl <50 mL/min) needed for sulfisoxazole
Terminal half-life 3.5-4.5 hours in normal renal function; prolonged to 10-15 hours with creatinine clearance <30 mL/min.
Renal: 70-80% as unchanged drug and active metabolite (sulfisoxazole); Biliary: 10-15% as metabolites; Fecal: <5%
Primarily renal (60-70% unchanged), with 20-30% as glucuronide conjugate; biliary/fecal <10%.
Category C
Category C
Macrolide and Sulfonamide Antibiotic
Sulfonamide Antibiotic